BlackRock, Inc. 13D and 13G filings for Karyopharm Therapeutics Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-07-08 4:32 pm Sale |
2024-06-30 | 13G | Karyopharm Therapeutics Inc. KPTI |
BlackRock Inc. BLK |
277,986 3.500% |
-393,459 (-58.60%) |
Filing |
| 2024-01-25 1:48 pm Purchase |
2023-12-31 | 13G | Karyopharm Therapeutics Inc. KPTI |
BlackRock Inc. BLK |
671,445 8.800% |
104,229 (+18.38%) |
Filing |
| 2023-01-26 08:52 am Unchanged |
2022-12-31 | 13G | Karyopharm Therapeutics Inc. KPTI |
BlackRock Inc. BLK |
567,216 10.500% |
0 (Unchanged) |
Filing |
| 2023-01-20 5:17 pm Sale |
2022-12-31 | 13G | Karyopharm Therapeutics Inc. KPTI |
BlackRock Inc. BLK |
567,216 10.500% |
-27,331 (-4.60%) |
Filing |
| 2022-01-27 5:13 pm Unchanged |
2021-12-31 | 13G | Karyopharm Therapeutics Inc. KPTI |
BlackRock Inc. BLK |
594,547 11.800% |
0 (Unchanged) |
Filing |
| 2022-01-26 09:16 am Purchase |
2021-12-31 | 13G | Karyopharm Therapeutics Inc. KPTI |
BlackRock Inc. BLK |
594,547 11.800% |
96,207 (+19.31%) |
Filing |
| 2021-01-26 6:52 pm Purchase |
2020-12-31 | 13G | Karyopharm Therapeutics Inc. KPTI |
BlackRock Inc. BLK |
498,340 10.200% |
4,086 (+0.83%) |
Filing |
| 2020-12-08 4:56 pm Purchase |
2020-11-30 | 13G | Karyopharm Therapeutics Inc. KPTI |
BlackRock Inc. BLK |
494,254 10.100% |
176,325 (+55.46%) |
Filing |